로딩 중…
StockDiggingStockDigging

WHANIN PHARM CO.,LTD

016580· KOSPI
₩10,140-1.55%
2026-06-19

Price Chart

WHANIN PHARM CO.,LTD-15.08%

Financials

Investment Metrics(as of 2026-06-19)

MetricValue
Size
Market Cap188.60B KRW
Revenue266.19B KRW
Net Income4.36B KRW
Total Assets481.97B KRW
Net Assets424.14B KRW
Employees653
Value
P/E43.28x
P/B0.44x
PEG0.94x
P/S0.71x
EV/EBITDA23.67x
FCF Yield4.08%
Profitability
ROE1.03%
ROA0.90%
Op. Margin2.10%
Revenue Growth18.23%
Earnings Growth45.82%
Financial Health
Debt Ratio113.64%
Total Debt2.01B KRW
FCF7.69B KRW
Cash58.43B KRW
Current Ratio4.10x
Net Debt/EBITDA-10.10x
Dividend
Div. Yield2.91%
Div. Growth0.00%
Performance
1Y Return-15.08%
1M Return-6.37%
From 52W High-23.24%
1Y MDD-23.69%
Trading
Volume121,378 shares
Foreign Own.11.08%
Per Share
EPS857 KRW
BPS22,947 KRW

Company Info

CEO 이광식, 이원범(각자 대표이사)
Employees 653
Founded 1982
HQ 서울특별시 송파구, KR

Established in 1978 and listed on the securities market in 1996, Whanin Pharmaceutical is a pharmaceutical manufacturing and sales company specializing in psychoneurotic agents. Based on 2024 IMS DATA, it holds the leading market share in the domestic psychotherapeutic drug market. With a robust drug lineup and strong network, the company boasts significant sales strengths in the psychoneurotic field and is growing with the market due to increasing prescriptions driven by the rise in mental health-related medical institutions and patient visits.